Trial
NCT06673069
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ionis Pharmaceuticals, Inc.
Collaborators
—
Condition
Alzheimer Disease
Intervention
ION269
Why stopped
Sponsor decision to terminate study early. Decision not based on safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-20